Submitting antibodies to binding arbitration
Stephen W Michnick1, Sachdev S Sidhu
1Département de Biochimie and Robert Cedergren Centre, Bioinformatique and Genomics, Université de Montréal, C.P. 6128, Succursale centre-ville, Montréal, Québec H3C 3J7, Canada. stephen.michnick@umontreal.ca
For the last 30 years, the production of affinity reagents and particularly antibodies for research and therapeutic applications has been dominated by hybridoma and polyclonal technologies, while more modern, reliable and inexpensive approaches have lagged. Here we discuss why this is the case and how a cultural shift in the biomedical research community could bring the new technologies for creating antibodies and other tailor-designed binding proteins into the mainstream, with the potential for myriad new applications in research and medicine.
For the last 30 years, the production of affinity reagents and particularly antibodies for research and therapeutic applications has been dominated by hybridoma and polyclonal technologies, while more modern, reliable and inexpensive approaches have lagged. Here we discuss why this is the case and how a cultural shift in the biomedical research community could bring the new technologies for creating antibodies and other tailor-designed binding proteins into the mainstream, with the potential for myriad new applications in research and medicine.
Related Concept Videos
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity

